Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 6/20 | 0.53 |
| ▸ | RAF1 | P04049 | 3/20 | 0.48 |
| ▸ | BRAF | P15056 | 3/20 | 0.48 |
| ▸ | CNR1 | P21554 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.44 |
| ▸ | RARA | P10276 | 2/20 | 0.44 |
| ▸ | RARB | P10826 | 2/20 | 0.44 |
| ▸ | RARG | P13631 | 2/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | NSD2 | O96028 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.42 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.42 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4516090 | 0.90 | ALDH1A1 (0.47) | MAPK14RAF1MAPTKMT2A | |
| SCHEMBL4502067 | 0.85 | MAPK14 (0.61) | MAPK14RAF1BRAFCNR1NR1H4 | |
| SCHEMBL4503633 | 0.85 | ALDH1A1 (0.50) | MAPK14NR1H4KMT2A | |
| SCHEMBL4516470 | 0.84 | RXRA (0.51) | MAPK14RARARARBRARG | |
| SCHEMBL3051455 | 0.83 | MAPK14 (0.56) | MAPK14BRAFNPC1RAB9AKMT2A | |
| SCHEMBL4506282 | 0.83 | MAPK14 (0.64) | MAPK14RAF1BRAF | |
| SCHEMBL4503416 | 0.83 | MAPK14 (0.55) | MAPK14RAF1RARAKMT2A | |
| SCHEMBL4504889 | 0.82 | MAPK14 (0.60) | MAPK14RAF1 | |
| SCHEMBL4510794 | 0.80 | MAPK14 (0.58) | MAPK14TP53MAPTNPC1RAB9A | |
| SCHEMBL4505916 | 0.80 | MAPK14 (0.55) | MAPK14RAF1BRAFNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286775-A1 | Bicyclic Derivatives as P38 Kinase Inhibitors | PALAU PHARMA, S.A. (ES) | 2009-11-19 | — | — | US | claimed |
| CN-101208301-A | Bicyclic derivatives as p38 kinase inhibitors | PALAU PHARMA SA (ES) | 2008-06-25 | — | — | CN | claimed |
| EP-1917241-A2 | BICYCLIC DERIVATIVES AS P38 KINASE INHIBITORS | Palau Pharma, S.A. (ES) | 2008-05-07 | — | — | EP | claimed |
| WO-2007000339-A1 | BICYCLIC DERIVATIVES AS P38 KINASE INHIBITORS | PALAU PHARMA, S.A. (ES) | 2007-01-04 | — | — | WO | claimed |
| US-20090286775-A1 | Bicyclic Derivatives as P38 Kinase Inhibitors | PALAU PHARMA, S.A. (ES) | 2009-11-19 | — | — | US | disclosed |
| CN-101208301-A | Bicyclic derivatives as p38 kinase inhibitors | PALAU PHARMA SA (ES) | 2008-06-25 | — | — | CN | disclosed |
| EP-1917241-A2 | BICYCLIC DERIVATIVES AS P38 KINASE INHIBITORS | Palau Pharma, S.A. (ES) | 2008-05-07 | — | — | EP | disclosed |
| WO-2007000339-A1 | BICYCLIC DERIVATIVES AS P38 KINASE INHIBITORS | PALAU PHARMA, S.A. (ES) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286775-A1 | Bicyclic Derivatives as P38 Kinase Inhibitors | MAPK1, MAPKAPK2, MAPKAPK3 | MAPK14 26/4885RAF1 71/4885BRAF 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.